SIS
SUPN icon

Sound Income Strategies’s Supernus Pharmaceuticals SUPN Stock Holding History

Sound Income Strategies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-287
Closed -$14.8K – 2171
2026
Q1 		$14.8K Buy
287
+137
+91% +$6.98K ﹤0.01% 1324
2025
Q4 		$7.5K Buy
+150
New +$7.29K ﹤0.01% 1621

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sound Income Strategies's SUPN Position: Q2 2026 in Review

Sound Income Strategies sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 287 shares — an estimated $14.8K sold.

Sound Income Strategies first reported a position in SUPN in Q4 2025 and held it in 2 quarters. The position peaked at $14.8K in Q1 2026. 248 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Sound Income Strategies reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 287 Supernus Pharmaceuticals shares in Q2 2026, an estimated $14.8K.
  • Sound Income Strategies first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Supernus Pharmaceuticals position peaked at $14.8K in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.